SI-BONE
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell SI-BONE and other ETFs, options, and stocks.About SIBN
SI-BONE, Inc. is a medical device company, which engages in the provision of a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of musculoskeletal disorders of the sacropelvic anatomy. It offers a proprietary minimally invasive surgical implant system, called iFuse, used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain.
CEOLaura A. Francis
CEOLaura A. Francis
Employees349
Employees349
HeadquartersSanta Clara, California
HeadquartersSanta Clara, California
Founded2008
Founded2008
Employees349
Employees349
SIBN Key Statistics
Market cap775.40M
Market cap775.40M
Price-Earnings ratio-34.98
Price-Earnings ratio-34.98
Dividend yield—
Dividend yield—
Average volume670.68K
Average volume670.68K
High today$17.92
High today$17.92
Low today$17.01
Low today$17.01
Open price$17.87
Open price$17.87
Volume970.94K
Volume970.94K
52 Week high$21.89
52 Week high$21.89
52 Week low$12.50
52 Week low$12.50
Stock Snapshot
The current SI-BONE(SIBN) stock price is $17.75, with a market capitalization of 775.4M. The stock trades at a price-to-earnings (P/E) ratio of -34.98.
During the trading session on 2026-01-13, SI-BONE(SIBN) shares reached a daily high of $17.92 and a low of $17.01. At a current price of $17.75, the stock is +4.4% higher than the low and still -0.9% under the high.
Trading volume for SI-BONE(SIBN) stock has reached 970.94K, versus its average volume of 670.68K.
Over the past 52 weeks, SI-BONE(SIBN) stock has traded between a high of $21.89 and a low of $12.50.
Over the past 52 weeks, SI-BONE(SIBN) stock has traded between a high of $21.89 and a low of $12.50.
Analyst ratings
100%
of 9 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own SIBN. This list is generated using Robinhood data, and it’s not a recommendation.